Paliperidona Sandoz (Paliperidone)

Paliperidone works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain. This antagonism reduces dopamine activity in pathways linked to psychosis while balancing serotonin effects, which together lessen hallucinations, delusions, and mood symptoms associated with schizophrenia and related disorders.

The dose of Paliperidona Sandoz is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate strength and titration schedule, following local labeling and clinical guidelines.

Paliperidone should only be used during pregnancy or lactation if the potential benefits justify the potential risks to the fetus or infant. Clinicians typically assess each case carefully, and women of child‑bearing potential are advised to discuss contraception and risk‑benefit considerations with their healthcare provider.

To request Paliperidona Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Paliperidone is the primary active metabolite of risperidone and shares a similar receptor profile, but it offers once‑daily oral dosing and a lower risk of certain metabolic side effects. Compared with older typical antipsychotics, it has a reduced propensity for extrapyramidal symptoms while still providing effective control of psychotic symptoms.

Paliperidona Sandoz tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Paliperidona Sandoz is supplied as oral tablets that are taken once daily, preferably at the same time each day, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their clinician.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, seizures, significant orthostatic hypotension, and cardiac arrhythmias such as QT prolongation. Patients should be monitored regularly for these events, and any concerning symptoms require immediate medical attention.

Paliperidona Sandoz is contraindicated in patients with known hypersensitivity to paliperidone or any excipients in the tablet, and in individuals with a history of neuroleptic malignant syndrome. Caution is also advised for patients with uncontrolled cardiovascular disease, severe hepatic impairment, or those taking interacting medications that cannot be adjusted.